Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients
BOSTON, Mass., and SEATTLE, Wash., and EMERYVILLE, Calif., June 15th, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation, wholly-owned gene editing tools, today announced a partnership to enable Affini-T’s next generation ex […]
Affini-T Therapeutics to Present at Upcoming Investor and Industry Conferences
BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced three presentations at upcoming investor and industry conferences. Jak Knowles, M.D., Co-founder, President and Chief Executive Officer of Affini-T Therapeutics, will present at each discussing the company’s T cell receptor (TCR) discovery platform, lead […]
Clinical Strategy for Enhancing Affini-T Therapeutics’ Merkel Polyoma Virus TCR Therapy to be Presented at ASCO 2022
BOSTON, Mass., and SEATTLE, Wash. – June 2, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that the clinical strategy for enhancing the efficacy of its Merkel cell polyomavirus (MCPyV)-specific T cell receptor (TCR) program for the treatment of PD-1 refractory Merkel cell carcinoma (MCC), from […]
Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy
BOSTON, Mass., and SEATTLE, Wash. – May 3, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its KRAS program will be presented in an oral presentation at the 25 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). […]
Affini-T Expands Board of Directors with Appointments of Michael Varney, Ph.D., and Daniel Faga
BOSTON, Mass., and SEATTLE, Wash. – April 5, 2022 – Affini-T Therapeutics, Inc, a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointments of Michael Varney, Ph.D., and Daniel Faga to its board of directors. “I am thrilled to welcome Mike and Dan to our board as both […]
Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations
Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D., and Vida Ventures along with serial entrepreneurs Arjun Goyal, M.D., M.Phil., and Jak Knowles, M.D. Foundational cell therapy platform builds upon seminal work from co-founders, leveraging a T Cell Receptor (TCR) discovery engine and suite of synthetic […]
Affini-T Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON, Mass., and SEATTLE, Wash., Jan. 10, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. Jak Knowles, M.D., Co-Founder, President and Chief Executive Officer, will present an overview of the company at 2:00 […]
